Aurobindo Pharma has received final USFDA approval for its generic Beclomethasone Dipropionate HFA Inhalation Aerosol. This marks the company's first-ever metered-dose inhaler product, targeting a $301 million US market.
Aurobindo Pharma announced on September 15, 2026, that it has received final approval from the US Food and Drug Administration (USFDA) for its Beclomethasone Dipropionate HFA Inhalation Aerosol in 40 mcg and 80 mcg strengths. This medication is a generic equivalent to the reference product QVAR, which is used for the maintenance treatment of asthma.
This approval is a notable shift in the company's product strategy. It marks the company's first entry into the metered-dose inhaler (MDI) segment. Unlike standard oral generic medications, inhalers involve complex technology and manufacturing processes, which generally limits the number of competitors in the space and can offer better profit margins. The product will be manufactured at the company's Aurolife Pharma facility located in Raleigh, North Carolina.
For investors, the market opportunity is significant. Data for the 12 months ending July 2026 estimates the US market for this specific treatment at approximately $301 million. With this addition, the company has reached a total of 596 ANDA (Abbreviated New Drug Application) approvals from the USFDA, reflecting its scale in the generic pharmaceutical sector.
Despite the positive regulatory update, the company’s share price closed slightly lower, with a decline ranging between 0.74% and 1.18% on the day of the announcement. This movement can sometimes reflect investors monitoring the execution speed and the competitive landscape of the generic inhalation market rather than the approval itself.
While this approval strengthens the company's portfolio, investors also monitor the broader regulatory health of the firm's manufacturing network. For instance, the company is managing ongoing compliance requirements at various sites, such as the warning letter issued by the USFDA for its Eugia Pharma Unit-I facility in August 2026. Maintaining consistent regulatory clearance across all manufacturing units is essential for the smooth launch and supply of new products like this inhaler.
The key monitorables for the coming quarters will be the speed at which Aurobindo Pharma can ramp up production and capture market share in this complex respiratory segment, as well as any updates regarding the resolution of pending regulatory compliance matters at other facilities.